Intensive chemotherapy, are there any other options?

During the EHA2021 Virtual Congress, Know AML spoke with Isolda Fernandez, FUNDALEU, Buenos Aires, AR. We asked, Are there any other options to intensive chemotherapy?

Addressing concerns around side effects in clinical trials

Know AML conducted a poll among patients with acute myeloid leukemia (AML), and their families and caregivers, revealing a concern regarding potential side effects that may be experienced during participation in a clinical trial.

Treating patients with FLT3-mutated AML: What you need to know

During the recent Know AML Ambassador Meeting, Professor Charles Craddock talked about treatments that are available for a type of acute myeloid leukemia (AML) with changes in the FLT3 gene, and discussed these with the other ambassadors.

How did long-term treatment with AML affect your lifestyle?

Know AML was pleased to speak with Ralph Hills, Know AML chair. We asked, How did long-term treatment affect your lifestyle?